MedPredict Thought Leader Insight & Analysis Reports
One of your key challenges is to stay on top of the latest activities in your target therapeutic categories. What’s happening with competitive compounds in the pipeline? What are their indications and marketing claims likely to be? How are trends in clinical practice evolving, and how will that affect your current and future business?
MedPredict delivers the insights that will drive your strategic decision-making, but without the big price tag and long lead-time required to conduct your own thought leader interviews or market research. We deliver a wide range of syndicated reports, based on in-depth, primary thought leader interviews, that are ready to download today, so you can act on the information right away. And if you don't see what you need in our syndicated reports database, we would be happy to provide you with a customized proposal for proprietary research.
Featured Report: Pharmacotherapies for Alcoholism Q1 2008
Price: USD $6,950
Report Summary: This report is derived from seven primary interviews conducted with North American specialists in the treatment of alcoholism. Six are psychiatrists and one is a general practitioner. All are highly active in research and alcoholism clinical trials.
Based on the lackluster commercial performance of naltrexone and acamprosate, Pharma has erroneously underestimated the size of the alcoholism market. The lack of clear FDA guidance on trial design and resulting indications has stymied many pharmaceutical companies from entering this category. There is a stigma associated with alcoholism. Companies may have a few product champions but the general corporate attitude is that developing drugs for alcoholism carries the same kind of corporate image risks as developing contraceptives and other “morality drugs”. There is also a tremendous fear of product liability litigation. The general corporate perception is that drugs for alcoholism won’t be reimbursable, and many of the people who come in for treatment will be “down and out” and not able to afford medicine. An analogy would be to forecast the size of the antidepressant market before the availability of Prozac.
We are however at an inflection point. While competitive intensity in the alcoholism field has been low by traditional measures it is clearly now emerging. We expect to see tremendous competitive growth after the first successful product launches into the primary care physician’s office.
To bring clarity to the debate on the course and speed of developments in this field the Panel tries to address a number of the underlying medical, regulatory, social and commercial issues. These include:
- Unmet needs from the patient, specialist, general practitioner, 3rd-party payer and societal perspective.
- Habits & practices of specialists, GPs and non-medical treaters.
- Hurdles preventing increased diagnosis and treatment of alcoholism, particularly in the community setting, and a commercialization model that Pharma can follow to overcome these.
- Changing paradigms in primary and secondary clinical trial endpoints and alcoholism trial designs.
- New screening tools and behavioral diagnostic instruments.
Who will benefit from this report: Competitive Intelligence, Marketing, Commercial Analysis, L&A, New Products Planning, R&D, Business Development and Market Research.